Li-Huei Tsai

This inventor holds 30 USPTO granted patents and 19 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Neurodegenerative Disorders. Top assignees: Massachusetts Institute of Technology, The General Hospital Corporation, The Broad Institute, Inc.. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Li-Huei Tsai. Retrieved from https://idiyas.com/inventor/li-huei-tsai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 19)

% Patents Active = 90.0

CIPO Patents = 3 (Patent Applications = 9)

EPO Patents = 7 (Patent Applications = 19)

Average Co-Inventor Count = 3.9

ph-index = 9

Forward Citations = 159(Granted Patents)

Company Filing History:

28 out of 8,586

Massachusetts Institute of Technology

patents

14 out of 3,073

The General Hospital Corporation

patents

6 out of 486

The Broad Institute, Inc.

The Brigham and Women's Hospital, Inc.

patents

6. 1 out of 1,628

University of Massachusetts

patents

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Neurodegeneration

Dementia Treatment

Gamma Oscillations

Microglia Reprogramming

Histone Deacetylase Inhibitors

Sirtuin Activators

Cholesterol Biosynthesis

Cognitive Function

Neuroinflammation

Transgenic Models

Epigenetic Mechanisms

Brain Tissue Integration

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12600942 - Reprogramming cells into homeostatic microglia (2026-04-14),

2. 12515069 - Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function (2026-01-06),

3. 12441987 - Multicellular integrated brain tissue in neurological diseases (2025-10-14),

4. 12384818 - Cyclin-dependent kinase 5 (CDK5) inhibitory peptides (2025-08-12),

5. 12318549 - Methods and devices for providing a stimulus to a subject to induce gamma oscillations (2025-06-03),

6. 12311194 - Systems and methods for preventing, mitigating, and/or treating dementia (2025-05-27),

7. 12296106 - Methods and devices for providing a stimulus to a subject to induce gamma oscillations (2025-05-13),

8. 12285440 - APOE4 impairs myelination via altered cholesterol biosynthesis and transport in oligodendroglia (2025-04-29),

9. 12201669 - Small molecule suppressors of APOE gene expression and cerebral vascular amyloid pathology (2025-01-21),

10. 11639325 - Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders (2023-05-02),

11. 11572368 - Inhibitors of histone deacetylase (2023-02-07),

12. 11241586 - Systems and methods for preventing, mitigating, and/or treating dementia (2022-02-08),

13. 11180438 - Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders (2021-11-23),

14. 11084803 - Activators of class I histone deacetylases (HDACs) and uses thereof (2021-08-10),

15. 10960225 - Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function (2021-03-30),

Title: The Innovative Contributions of Li-Huei Tsai

Introduction

Li-Huei Tsai, a prominent inventor based in Cambridge, MA, has made significant contributions to the field of neurodegenerative research and treatment. With an impressive portfolio of 22 patents, her work is primarily focused on innovations that aim to combat diseases such as Alzheimer’s.

Latest Patents

Among her latest patents are cutting-edge inventions that hold promise for improving the treatment of neurodegenerative disorders. One notable patent discusses "Small molecule suppressors of APOE gene expression and cerebral vascular amyloid pathology." This invention provides methods for inhibiting amyloid synthesis in subjects, particularly beneficial for treating diseases linked to amyloid, such as Alzheimer’s disease. The small molecule inhibitors included in this patent are designed to be non-immunosuppressant cyclosporins, alongside their pharmaceutically acceptable salts.

Another significant invention is related to "Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders." This patent focuses on polyhydroxylated benzophenone compounds that are useful in treating various neurodegenerative, neurological, psychiatric, and cognitive diseases, especially those associated with a deficiency in HDAC1 deacetylase activity.

Career Highlights

Li-Huei Tsai has an outstanding career in research and innovation, notably contributing her expertise at esteemed institutions like the Massachusetts Institute of Technology and The General Hospital Corporation. Her commitment to advancing understanding and treatment of neurodegenerative diseases has positioned her as a leading figure in her field.

Collaborations

Throughout her career, Tsai has collaborated with notable professionals, including Stephen J. Haggarty and Edward Holson. These collaborations have fostered advancements in understanding the mechanisms behind neurodegenerative diseases and have catalyzed the development of her groundbreaking patents.

Conclusion

Li-Huei Tsai’s extensive work and innovations are paving the way for future advancements in the treatment of neurodegenerative diseases. With her 22 patents, she continues to contribute to the scientific community’s understanding and treatment of these complex disorders, solidifying her role as a pioneering inventor in the realm of medical research.

Profile summary based on public USPTO records.